All In Biotech

Drug Trial Radar · NCT06345794

A Study to Assess LY4100511 (DC-853) in Healthy Adult Participants

A Phase 1, Single-Center, Open-Label, 3-Cohort, Fixed-Sequence, Drug-Drug Interaction Study To Assess The Pharmacokinetics Of LY4100511 (DC-853) When Orally Administered Alone, When Coadministered With Itraconazole, Fluconazole, Or Carbamazepine In Healthy Adult Participants

Last checked: Nov 19, 2026Latest source record: Apr 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

50

Actual

Start

Apr 3, 2024

Primary completion

Jun 18, 2024

Study completion Jun 18, 2024

Sponsor

Sponsor type
Industry
Collaborators
Eli Lilly and Company
First posted
Apr 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main purpose of this study is to assess the effect of multiple doses of itraconazole, fluconazole, and carbamazepine on single dose pharmacokinetic of LY4100511 (DICE-853) in healthy participants. The study will also evaluate the safety and tolerability of LY4100511 (DICE-853) with itraconazole, fluconazole, and carbamazepine.

Conditions

  • Healthy

Interventions

  • LY4100511 (DC-853)Drug

    Administered orally.

  • ItraconazoleDrug

    Administered orally.

  • FluconazoleDrug

    Administered orally.

  • CarbamazepineDrug

    Administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY4100511 (DC-853)Time frame: Predose up to 26 Days
  2. PK: PK: Area Under the Concentration Versus Time Curve From Zero to Last Measurable Concentration (AUC[0-t]) of LY4100511 (DC-853)Time frame: Predose up to 26 Days
  3. PK: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-inf]) of LY4100511 (DC-853)Time frame: Predose up to 26 Days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ICON San Antonio Clinical Research Unit

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.